May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Safety and Efficacy Assessment of Intravitreal Bevacizumab for Retinal Disorders
Author Affiliations & Notes
  • K. W. Tai
    New York Eye and Ear Infirmary, New York, New York
    Ophthalmology Clinical Research,
  • C. Nayar
    Fordham University, New York, New York
  • S. Harris
    St. Georges University, Grenada, West Indies, United States Virgin Islands
  • R. C. Gentile
    New York Eye and Ear Infirmary, New York, New York
    Ophthalmology,
  • R. B. Rosen
    New York Eye and Ear Infirmary, New York, New York
    Ophthalmology,
  • Footnotes
    Commercial Relationships  K.W. Tai, None; C. Nayar, None; S. Harris, None; R.C. Gentile, None; R.B. Rosen, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 2110. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K. W. Tai, C. Nayar, S. Harris, R. C. Gentile, R. B. Rosen; Safety and Efficacy Assessment of Intravitreal Bevacizumab for Retinal Disorders. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2110.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Bevacizumab (Avastin) is an anti-VEGF agent used in approved for use in metastatic colorectal carcinoma (FDA Approved). This study analyzes the safety and efficacy of off-label Intravitreal Injection of bevacizumab (Avastin) for CNVM, Wet AMD, Macular edema due to diabetic retinopathy, vascular occlusion and other retinal disorders.

Methods: : Retrospective chart review recording vision change, anatomical changes (Regression of NVE, CNVM, reduction in macular thickness); central thickness changes measured by (OCT) and OCT-SLO. Ocular side effects (infection, RD, IOP rise, cataract) were also recorded.

Results: : 487 eyes with retinal disorders which received intravitreal injection of bevacizumab showed slight visual acuity improvement. Ten percent of the treated eyes needed bevacizumab retreatment within 1 year. Ocular side effects (infection, RD, IOP rise, cataract) were not seen.

Conclusions: : Evaluation of 487 eyes with retinal disorders which received intravitreal injection of bevacizumab showed that bevacizumab was well tolerated and had little to no side effect findings.

Keywords: clinical (human) or epidemiologic studies: outcomes/complications • clinical (human) or epidemiologic studies: risk factor assessment • clinical (human) or epidemiologic studies: prevalence/incidence 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×